Thursday, February 13, 2020

PLGA from PolySciTech used in evaluation of 3D Cell culturing of cancer cells as assay tool.



Testing cancer therapies requires making sure that the test used is relevant to the physiology of the patient. Ideally, cancer cells will be grown in a 3D format, same as they are in the human body. Recently, researchers at San Jose State University used PLGA (AP042) from PolySciTech (www.polyscitech.com) to create doxorubicin nanoparticles for testing the accuracy of 3D Cell cultures. This research holds promise for improved research in cancer therapy in the future. Read more: Nimbalkar, Priya, Peter Tabada, Anuja Bokare, Jeffrey Chung, Marzieh Mousavi, Melinda Simon, and Folarin Erogbogbo. "Improving the physiological relevance of drug testing for drug-loaded nanoparticles using 3D tumor cell cultures." MRS Communications 9, no. 3 (2019): 1053-1059. https://www.cambridge.org/core/journals/mrs-communications/article/improving-the-physiological-relevance-of-drug-testing-for-drugloaded-nanoparticles-using-3d-tumor-cell-cultures/FEAC0E69F94D331886A06FFD2E854D0A

Nanoparticle-mediated drug delivery has the potential to overcome several limitations of cancer chemotherapy. Lipid polymer hybrid nanoparticles (LPHNPs) have been demonstrated to exhibit superior cellular delivery efficacy. Hence, doxorubicin (a chemotherapeutic drug)-loaded LPHNPs have been synthesized by three-dimensional (3D)-printed herringbone-patterned multi-inlet vortex mixer. This method offers rapid and efficient mixing of reactants yielding controllable and reproducible synthesis of LPHNPs. The cytotoxicity of LPHNPs is tested using two-dimensional (2D) and 3D microenvironments. Results obtained from 3D cell cultures showed major differences in cytotoxicity in comparison with 2D cultures. These results have broad implications in predicting in vitro LPHNP toxicology.

--> Save-the-date: Akina, Inc's third annual Biotech-Pharma-Cancer-Research (BPCR) conference is August 26 at Kurz Purdue Technology Center (KPTC) (http://bpcrconference.com/).

No comments: